114 related articles for article (PubMed ID: 7781871)
1. Efficacy of ipriflavone and 1 alpha vitamin D therapy for the cessation of vertebral bone loss.
Ushiroyama T; Okamura S; Ikeda A; Ueki M
Int J Gynaecol Obstet; 1995 Mar; 48(3):283-8. PubMed ID: 7781871
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
[TBL] [Abstract][Full Text] [Related]
3. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
[TBL] [Abstract][Full Text] [Related]
4. Effects of the combined use of calcitonin and 1 alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin.
Ushiroyama T; Ikeda A; Sakai M; Higashiyama T; Ueki M
Maturitas; 2001 Dec; 40(3):229-38. PubMed ID: 11731184
[TBL] [Abstract][Full Text] [Related]
5. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
Kovács AB
Agents Actions; 1994 Mar; 41(1-2):86-7. PubMed ID: 8079827
[TBL] [Abstract][Full Text] [Related]
7. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin.
Fujita T; Fujii Y; Miyauchi A; Takagi Y
J Bone Miner Metab; 1999; 17(4):289-95. PubMed ID: 10575594
[TBL] [Abstract][Full Text] [Related]
9. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
[TBL] [Abstract][Full Text] [Related]
10. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
11. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
Nozaki M; Hashimoto K; Inoue Y; Ogata R; Okuma A; Nakano H
Int J Gynaecol Obstet; 1998 Jul; 62(1):69-75. PubMed ID: 9722129
[TBL] [Abstract][Full Text] [Related]
12. The effect of an ipriflavone-containing supplement on urinary N-linked telopeptide levels in postmenopausal women.
Halpner AD; Kellermann G; Ahlgrimm MJ; Arndt CL; Shaikh NA; Hargrave JJ; Tallas PG
J Womens Health Gend Based Med; 2000 Nov; 9(9):995-8. PubMed ID: 11103099
[TBL] [Abstract][Full Text] [Related]
13. Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D.
Sato Y; Kuno H; Kaji M; Saruwatari N; Oizumi K
Am J Phys Med Rehabil; 1999; 78(5):457-63. PubMed ID: 10493456
[TBL] [Abstract][Full Text] [Related]
14. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women.
Ushiroyama T; Ikeda A; Ueki M
Maturitas; 2002 Mar; 41(3):211-21. PubMed ID: 11886767
[TBL] [Abstract][Full Text] [Related]
15. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.
Agnusdei D; Gennari C; Bufalino L
Osteoporos Int; 1995; 5(6):462-6. PubMed ID: 8695969
[TBL] [Abstract][Full Text] [Related]
16. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
17. [Ipriflavone].
Kitatani K; Morii H
Nihon Rinsho; 1998 Jun; 56(6):1537-43. PubMed ID: 9648478
[TBL] [Abstract][Full Text] [Related]
18. Increase in femoral bone mass by ipriflavone alone and in combination with 1 alpha-hydroxyvitamin D3 in growing rats with skeletal unloading.
Notoya K; Yoshida K; Tsukuda R; Taketomi S; Tsuda M
Calcif Tissue Int; 1996 Feb; 58(2):88-94. PubMed ID: 8998683
[TBL] [Abstract][Full Text] [Related]
19. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Piaggesi L; Genazzani AR
Maturitas; 1997 Sep; 28(1):75-81. PubMed ID: 9391998
[TBL] [Abstract][Full Text] [Related]
20. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
